Camp4 Therapeutics outlined a new SYNGAP program aimed at treating haploinsufficient CNS disorders by upregulating gene expression. The company said the approac

Camp4 Therapeutics outlined a new SYNGAP program aimed at treating haploinsufficient CNS disorders by upregulating gene expression. The company said the approach targets SYNGAP1 and comes ahead of a planned clinical trial, extending its regulatory RNA strategy.